NURS 5434
UTA Family 3 Final | Practice
Questions, Answers & Detailed
Rationales
Resource Features
➢ NURS 5434 Family III practice questions
➢ Final-exam review
➢ Detailed answers and rationales
➢ Clinical case scenarios
➢ Differential-diagnosis practice
, UTA NURS 5434 Family 3 Final |
Practice Questions, Answers & Detailed
Rationales
Question 1
The USPSTF recommends colorectal cancer screening starting
at what age with a Grade A recommendation?
A) Age 45
B) Age 50-75
C) Age 76-85
D) Age 40
Answer: B) Age 50-75
Rationale: The USPSTF gives a Grade A recommendation for
colorectal cancer screening in adults aged 50-75 years. Grade B is
given for ages 45-49 (average risk, asymptomatic), and Grade I
(insufficient evidence) is assigned for ages 76-85, where screening
should be based on overall health, benefits, and patient
preference.
,Question 2
A 28-year-old woman with normal Pap smears asks about
cervical cancer screening. According to USPSTF guidelines,
what is the recommended screening interval for women aged
30-65?
A) Every year with cervical cytology
B) Every 2 years with HPV testing
C) Every 3 years with cervical cytology alone, every 5 years with
hrHPV testing alone, or every 5 years with cotesting
D) Only if symptomatic
Answer: C) Every 3 years with cervical cytology alone, every 5
years with hrHPV testing alone, or every 5 years with
cotesting
Rationale: For women aged 30-65, the USPSTF recommends
screening every 3 years with cervical cytology alone, every 5 years
with high-risk human papillomavirus (hrHPV) testing alone, or
every 5 years with hrHPV testing in combination with cytology
(cotesting). All options receive a Grade A recommendation. For
, women aged 21-29, screening every 3 years with cervical cytology
alone is recommended.
Question 3
Which patient population should undergo risk assessment
and possible genetic counseling for BRCA1/2 mutations
according to USPSTF guidelines?
A) All women over age 50
B) Women with a personal or family history of breast, ovarian,
tubal, or peritoneal cancer or ancestry associated with BRCA1/2
gene mutation
C) All women with dense breast tissue
D) Women with a history of benign breast disease
Answer: B) Women with a personal or family history of
breast, ovarian, tubal, or peritoneal cancer or ancestry
associated with BRCA1/2 gene mutation
Rationale: The USPSTF recommends risk assessment for women
with a personal or family history of breast, ovarian, tubal, or
peritoneal cancer, or an ancestry associated with BRCA1/2 gene
UTA Family 3 Final | Practice
Questions, Answers & Detailed
Rationales
Resource Features
➢ NURS 5434 Family III practice questions
➢ Final-exam review
➢ Detailed answers and rationales
➢ Clinical case scenarios
➢ Differential-diagnosis practice
, UTA NURS 5434 Family 3 Final |
Practice Questions, Answers & Detailed
Rationales
Question 1
The USPSTF recommends colorectal cancer screening starting
at what age with a Grade A recommendation?
A) Age 45
B) Age 50-75
C) Age 76-85
D) Age 40
Answer: B) Age 50-75
Rationale: The USPSTF gives a Grade A recommendation for
colorectal cancer screening in adults aged 50-75 years. Grade B is
given for ages 45-49 (average risk, asymptomatic), and Grade I
(insufficient evidence) is assigned for ages 76-85, where screening
should be based on overall health, benefits, and patient
preference.
,Question 2
A 28-year-old woman with normal Pap smears asks about
cervical cancer screening. According to USPSTF guidelines,
what is the recommended screening interval for women aged
30-65?
A) Every year with cervical cytology
B) Every 2 years with HPV testing
C) Every 3 years with cervical cytology alone, every 5 years with
hrHPV testing alone, or every 5 years with cotesting
D) Only if symptomatic
Answer: C) Every 3 years with cervical cytology alone, every 5
years with hrHPV testing alone, or every 5 years with
cotesting
Rationale: For women aged 30-65, the USPSTF recommends
screening every 3 years with cervical cytology alone, every 5 years
with high-risk human papillomavirus (hrHPV) testing alone, or
every 5 years with hrHPV testing in combination with cytology
(cotesting). All options receive a Grade A recommendation. For
, women aged 21-29, screening every 3 years with cervical cytology
alone is recommended.
Question 3
Which patient population should undergo risk assessment
and possible genetic counseling for BRCA1/2 mutations
according to USPSTF guidelines?
A) All women over age 50
B) Women with a personal or family history of breast, ovarian,
tubal, or peritoneal cancer or ancestry associated with BRCA1/2
gene mutation
C) All women with dense breast tissue
D) Women with a history of benign breast disease
Answer: B) Women with a personal or family history of
breast, ovarian, tubal, or peritoneal cancer or ancestry
associated with BRCA1/2 gene mutation
Rationale: The USPSTF recommends risk assessment for women
with a personal or family history of breast, ovarian, tubal, or
peritoneal cancer, or an ancestry associated with BRCA1/2 gene
